Rivaroxaban 10 mg Daily Dosing Guidelines

Perioperative Bridging and Dosing Considerations

A reduced dose of 10 mg once daily can be used as a bridging strategy for 2-3 days after high bleeding risk surgery in patients who require long-term anticoagulation for atrial fibrillation or venous thromboembolism (VTE), before resuming full treatment doses, as recommended by the American College of Cardiology 1, 2
The American Heart Association suggests starting the bridging dose on the morning after surgery (24 hours postoperatively) and continuing for 2 days, then increasing to treatment dose (20 mg once daily for atrial fibrillation or VTE treatment) 1, 2

The American College of Chest Physicians recommends avoiding concomitant use with combined strong CYP3A4 and P-glycoprotein inhibitors (ketoconazole, itraconazole, voriconazole, posaconazole, HIV protease inhibitors) as they can increase rivaroxaban exposure by approximately 2.5-fold, significantly increasing bleeding risk 3, 4
The International Society on Thrombosis and Haemostasis suggests using strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort) with caution as they can decrease rivaroxaban exposure by 50%, potentially reducing efficacy 3, 4

The European Society of Cardiology recommends using rivaroxaban with caution in elderly patients (>75 years), particularly those with multiple comorbidities 5, 6
The National Comprehensive Cancer Network suggests using rivaroxaban with caution in patients with low body weight (<50 kg), though dose adjustment is not routinely required 7, 4